Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | LAP3 | P28838 | 3/20 | 0.35 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 3/20 | 0.31 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8530586 | 1.00 | CA2 (0.35) | CA2LAP3FDPSMMP2CA12 | |
| Hydrochloric Acid SCHEMBL27794619 | 0.97 | CA2 (0.33) | CA2LAP3FDPSMMP2CA12 | |
| SCHEMBL29182604 | 0.80 | CA2 (0.35) | CA2LAP3FDPSMMP2CA12 | |
| SCHEMBL8579001 | 0.78 | CA2 (0.33) | CA2LAP3FDPSMMP2CA12 | |
| SCHEMBL6129833 | 0.78 | CA2 (0.33) | CA2LAP3FDPSMMP2CA12 | |
| SCHEMBL11157525 | 0.75 | LAP3 (0.32) | CA2LAP3FDPS | |
| Hydrochloric Acid SCHEMBL1194147 | 0.75 | CA2 (0.39) | CA2LAP3 | |
| SCHEMBL8964718 | 0.75 | FDPS (0.36) | CA2LAP3FDPS | |
| SCHEMBL20087414 | 0.75 | LAP3 (0.38) | CA2LAP3FDPSANPEPERAP1 | |
| SCHEMBL3062829 | 0.73 | CA2 (0.35) | CA2LAP3FDPSMMP2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720050-A1 | PROCESS OF PREPARING HIV CAPSID INHIBITOR | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | claimed |
| WO-2024249672-A1 | PROCESS OF PREPARING HIV CAPSID INHIBITOR | GILEAD SCIENCES, INC. (US) | 2024-12-05 | — | — | WO | claimed |
| CN-117586300-A | Nucleoside triphosphate intermediate Bis-O- (9 h-fluorene-9-methyl) -n, n-diisopropyl phosphoramidate and preparation method thereof | 精华制药集团南通有限公司 | 2024-02-23 | — | — | CN | claimed |
| CN-117586331-A | Key intermediate of 5-fluorouracil deoxynucleoside triphosphate and preparation method thereof | 精华制药集团南通有限公司 | 2024-02-23 | — | — | CN | claimed |
| EP-1756101-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | Acadia Pharmaceuticals Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005115361-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIA PHARMACEUTICALS INC. (US) | 2005-12-08 | — | — | WO | claimed |
| EP-4720050-A1 | PROCESS OF PREPARING HIV CAPSID INHIBITOR | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250261553-A1 | NOVEL COMPOUND, CONJUGATED POLYMER AND METHOD FOR PRODUCING SAME, FILM FORMATION COMPOSITION, ORGANIC THIN FILM AND ORGANIC SEMICONDUCTOR ELEMENT | TOSOH CORPORATION (JP) | 2025-08-14 | — | — | US | disclosed |
| WO-2025089261-A1 | ORGANIC TRANSISTOR | 東ソー株式会社 | 2025-05-01 | — | — | WO | disclosed |
| CN-119776355-A | Bivalent aptamer for glucose small molecules, and preparation method and application thereof | 华南理工大学 | 2025-04-08 | — | — | CN | disclosed |
| EP-4516794-A1 | NOVEL COMPOUND, CONJUGATED POLYMER AND METHOD FOR PRODUCING SAME, FILM FORMATION COMPOSITION, ORGANIC THIN FILM, AND ORGANIC SEMICONDUCTOR ELEMENT | Tosoh Corporation (JP) | 2025-03-05 | — | — | EP | disclosed |
| WO-2024249672-A1 | PROCESS OF PREPARING HIV CAPSID INHIBITOR | GILEAD SCIENCES, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-118201942-A | Modified short interfering nucleic acid (siNA) molecules and uses thereof | 阿利戈斯治疗公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2006120576-A2 | IMMUNOGENS FOR MENINGITIDIS-A VACCINES | NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006112872-A2 | OLIGONUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006093526-A2 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2005115361-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIA PHARMACEUTICALS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| EP-1366048-A2 | PYRAZOLOPYRIDINE DERIVATIVES | SmithKline Beecham Corporation (US) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072581-A2 | PYRAZOLOPYRIADINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-19 | — | — | WO | disclosed |
| WO-1998011120-A1 | A METHOD OF NUCLEIC ACID SEQUENCING | DUKE UNIVERSITY (US) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250261553-A1 | NOVEL COMPOUND, CONJUGATED POLYMER AND METHOD FOR PRODUCING SAME, FILM FORMATION COMPOSITION, ORGANIC THIN FILM AND ORGANIC SEMICONDUCTOR ELEMENT | CD99, SOAT2, SOAT1 | CA2 3716/4885LAP3 4870/4885FDPS 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.